Why the Rare Event Is the Real Signal in Biotech

Apr 21, 2026

9 min read

3 views

85%

The mistake most investors and scientists make

We are trained to think in straight lines. A small improvement is worth a little more, a bigger improvement is worth a little more still, and valuation should rise in proportion to progress. But biology, markets, and human judgment do not work that way. In all three, rarity is not additive, it is exponential.

That is why the same event can look ordinary through a linear lens and astonishing through a logarithmic one. A probability cut in half is not just a bit rarer. It is twice as surprising. In information terms, the surprise does not increase linearly, it stacks. This matters because the most important technologies are not the ones that are merely better. They are the ones that move from the realm of the expected into the realm of the previously impossible.

Prime editing belongs to that second category. Its promise is not just another incremental tool in the gene editing toolbox. It is a search and replace function for DNA, a way to correct specific genetic errors rather than simply cut, disrupt, or workaround them. That is not a small improvement. It is a shift in the class of problem humanity can solve.

The deeper question is this: how do we value something whose significance grows nonlinearly as it becomes more plausible?

Why surprise is the right unit for breakthrough science

There is a reason entropy is defined in terms of surprise. Information is not about how much something changes in the abstract. It is about how much uncertainty collapses when reality reveals itself. If a result was already likely, it tells you little. If it was thought to be nearly impossible and then happens anyway, it rewrites your model of the world.

That is the hidden parallel between entropy and breakthrough science. A technology that repairs DNA precisely does more than add capability. It reduces the entropy of medicine. It turns a diffuse, uncertain landscape of symptoms, substitutions, and compromises into a more legible space where specific errors can be found and corrected.

Consider the difference between the old model and the new one:

Old model: alter the system broadly and hope the downstream effects are acceptable.
New model: identify the exact defect, replace the exact letter, and preserve the rest.

This is the difference between patching a roof with tar and replacing the broken tile. One is improvisation. The other is precision.

The market often misses this because markets are fluent in linear extrapolation. If a company has one good scientific platform, the instinct is to price it as one more interesting biotech. But a platform that can repeatedly convert the impossible into the plausible has a different shape. It is not a single product. It is a new probability engine.

The rarest thing in innovation is not invention itself. It is a technology that makes rare outcomes reproducible.

That is why scientific pedigree matters, but not in the shallow prestige sense. When a field is built by people who have already redefined what is technically possible, the probability distribution itself can shift. A breakthrough is not just an idea. It is a compression of uncertainty by expertise, method, and timing.

Prime editing as a logarithmic technology

Most technologies scale linearly in user impact. A better battery gives somewhat more range. A faster chip gives somewhat more throughput. Prime editing is different because it potentially scales logarithmically in consequence. Each additional successful correction is not merely one more fix. It is one more proof that a formerly inaccessible class of diseases can be addressed with precision.

Think of it like language correction. If a sentence contains a typo, a blunt tool might delete the whole word and hope the meaning survives. A precise editor changes one letter and preserves the message. Now imagine that sentence is a gene, and the typo causes a severe disease. The value of exact correction is not just technical elegance. It is the difference between treating a condition and genuinely restoring function.

This is where linear thinking fails.

A linear mindset asks: how much better is this than current tools? A logarithmic mindset asks: how many orders of magnitude of capability does this unlock? Because once a method can reliably edit DNA with specificity, the relevant question is no longer whether it helps one disease. It is whether it creates a platform for many diseases, many mutations, and many future applications we cannot yet name.

The distinction is subtle but crucial:

Incremental innovation improves the slope of an existing curve.
Platform innovation changes the curve itself.
Category-defining innovation changes how we measure the curve.

Prime editing is compelling because it may belong to the third group. If it works as hoped, it does not merely occupy a niche in therapeutic development. It redefines what counts as a feasible intervention.

And that is why the market cap debate is not really about one company. It is about whether people understand the economics of rare events. A technology that makes a once-vanishingly improbable therapeutic outcome reliable deserves to be valued by a different logic than a standard drug program.

The hidden economy of rare events

In finance, science, and life, we usually overpay for the familiar and underpay for the improbable until the improbable starts compounding.

That is because humans are not naturally logarithmic thinkers. We intuitively feel a risk doubling from 1 percent to 2 percent. But we do not intuitively feel the difference between 0.1 percent and 0.05 percent, even though the latter is a much deeper regime of improbability. The log scale reveals what intuition hides: each halving of probability carries the same informational weight.

Now apply that to biotech.

A therapy that can repair a few obvious mutations is useful. A therapy that can systematically address mutation classes is transformative. A therapy that can do so with enough precision, safety, and flexibility to become routine is civilization shifting. The gap between each stage is not just a little bigger. It is a different order of rarity.

This is why some scientific advances feel overhyped at first and then, all at once, look obvious in retrospect. The world does not update smoothly. It updates in jumps. People wait for certainty, but certainty arrives late, after the informational value has already been created.

The real investor advantage, and the real intellectual advantage, is to ask:

What outcome looks implausible to the crowd but becomes probable under a new technology?
What does the world look like if this works repeatedly rather than once?
Which assumptions are linear only because our minds are?

These questions matter because the value of a rare event is not just in the event itself. It is in the reclassification of the possible.

A framework for thinking about transformative biotech

Here is a simple way to evaluate technologies like this without getting lost in hype.

1. Ask whether the technology changes the unit of intervention

Does it merely improve an existing treatment, or does it change what can be targeted at all? A drug that reduces symptoms is different from a tool that edits the causal code.

2. Ask whether the technology reduces uncertainty, not just severity

The best technologies do not only make bad outcomes smaller. They make outcomes more legible. Precision editing matters because it creates a path from uncertainty to control.

3. Ask whether success compounds across use cases

If one platform can be applied to many mutations, diseases, or contexts, then each success is not isolated. It increases confidence in the platform itself, which changes valuation in a non-linear way.

4. Ask whether the market is pricing the next experiment or the next regime

A market often prices the next visible milestone. But the largest gains come from recognizing a regime change before consensus does. That is the difference between owning a promising asset and owning a future standard.

This framework helps explain why some technologies look expensive at first glance and cheap in hindsight. The pricing error is often a mismatch between linear valuation and logarithmic possibility.

A useful analogy is chess. A small positional advantage can be meaningless, or it can be the beginning of a forced win depending on board geometry. Similarly, a modest scientific improvement may be unimpressive in isolation, yet decisive if it unlocks a previously blocked pathway. The key is to see not just the move, but the board.

The practical lesson: think in orders of magnitude, not headlines

Whether you are an investor, a scientist, or simply a careful observer of change, the lesson is the same: do not confuse what is easy to name with what is easy to understand.

A headline says a company is promising. A deeper reading asks whether the underlying technology changes the probability distribution of medical success. A casual observer sees another biotech name. A serious thinker asks whether this is a new grammar for intervention.

This is where entropy becomes more than a math concept. It becomes a discipline of thought. Low-entropy thinking is rigid, overconfident, and linear. High-quality thinking notices uncertainty, measures surprise, and updates proportionally to the rarity of the evidence.

In practice, that means:

Being skeptical of simple comparisons between a breakthrough platform and conventional therapeutics.
Paying attention to whether a technology can repeatedly achieve precise outcomes, not just generate compelling early stories.
Recognizing that the most valuable scientific advances often look impractical until the day they look inevitable.

The hardest thing to do is to value the future before it has become familiar. But that is exactly where the interesting opportunities live.

Key Takeaways

Use logarithmic thinking for breakthrough technologies. A result that halves the probability of failure or expands precision dramatically is more than a linear improvement.
Evaluate platforms by the class of problems they unlock. The question is not whether a tool helps one disease, but whether it changes what becomes medically possible.
Treat surprise as a signal, not noise. In science and investing, the most meaningful events are often those that initially seem too improbable to matter.
Look for technologies that reduce uncertainty, not just severity. The best innovations make the world more editable, not just less painful.
Price the regime, not the headline. Many transformative opportunities are misread because the market values the next visible milestone instead of the new probability landscape.

Conclusion: the future belongs to the technologies that make rarity routine

The deepest promise of precise gene editing is not simply that it can fix disease. It is that it can take what once felt miraculous and make it methodical. That is the real pattern shared by entropy and innovation: when something rare becomes repeatable, the world has changed categories.

We usually ask whether a technology is good enough. A better question is whether it changes the meaning of surprise. If it does, then we are no longer talking about an improvement. We are talking about a new coordinate system for what can happen next.

And once you learn to see that, linear thinking starts to look like a historical artifact.